Metabolic Pharmaceuticals Ltd - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Metabolic Pharmaceuticals Ltd Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Metabolic Pharmaceuticals Ltd. The Company's principal activities are developing platforms for the oral delivery of injectable peptide drugs and focusing on taking drug candidates through research, formal preclinical and clinical development. The company's lead project is Oral Peptide Delivery Platform, which develops oral versions of injectable peptide drugs with enhanced absorption. It also plans to prioritize this project to become an important source of in-house development of new drugs. Other projects such as the Obesity Project, and Neuropathic Pain Project, which were developing the drugs AOD9604 and ACV1 respectively, had been discontinued due to lack of evidence of efficacy. The Company is also developing AOD9604 for the potential prevention and / or treatment of osteoporosis. It operates in Australia.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report